fda import alert semaglutide tirzepatide green list September 8, 2025: launches an listing safe GLP-1 manufacturers – Partnership for Safe Medicines Recently, the U.S. FDA send

Description

At our practice, we determine the optimal injection interval and treatment schedule through regular follow-up appointments

Access to our data PSM makes our shipment-level data available to a group of manufacturer brand protection teams, law enforcement, and regulators

This head-to-head comparison with the leading GLP-1 receptor agonist demonstrated tirzepatides superiority across all efficacy endpoints

Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/m Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes, said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research

Data presented are for the efficacy estimand unless otherwise noted AHI apneahypopnea index (measured by polysomnography and reported in events per hour of sleep), CV cardiovascular, HF heart failure, HFpEF heart failure with preserved ejection fraction, hsCRP high-sensitivity C-reactive protein, KCCQ-CSS Kansas City Cardiomyopathy Questionnaire clinical summary score (range of 0100, with higher numbers indicating better quality of life), MASH metabolic dysfunctionassociated steatohepatitis, NASH nonalcoholic steatohepatitis, OSA obstructive sleep apnea, PAP positive airway pressure, SASHB sleep apnea-specific hypoxic burden, SBP systolic blood pressure, T2D type 2 diabetes Table 4